Filana Therapeutics (FLNA) Cash & Equivalents (2010 - 2026)

Filana Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $82.7 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 26.43% year-over-year to $82.7 million; the TTM figure through Jun 2026 stood at $82.7 million (down 26.43% YoY), while the FY2025 annual figure was $95.5 million, down 25.72% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $82.7 million, down from $86.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $209.7 million in Q1 2022, with the low at $82.7 million in Q2 2026.
• The 5-year median for Cash & Equivalents is $135.5 million (2023), against an average of $145.1 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents grew 23.07% in 2024, then sank 45.79% in 2025.
• Filana Therapeutics' Cash & Equivalents stood at $201.0 million in 2022, then plunged by 39.74% to $121.1 million in 2023, then advanced by 6.14% to $128.6 million in 2024, then dropped by 25.72% to $95.5 million in 2025, then decreased by 13.42% to $82.7 million in 2026.
• Business Quant data shows FLNA's Cash & Equivalents at $82.7 million in Q2 2026, $86.6 million in Q1 2026, and $95.5 million in Q4 2025.